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Individuals with chronic conditions, such as asthma, on average incur high health care costs 
though good control can reduce costs and improve health outcomes. However, there may be 
substantial variation between patients in their use of services and therefore costs. Our 
objective was to investigate the sources of such variation in health system and out-of-pocket 
costs for people with asthma. 
Methods 
A longitudinal observational study of 252 people with asthma followed for three years, using 
six-monthly postal surveys and individual administrative data.  Factors associated with costs 
were investigated using generalised linear mixed models. 
Results 
There was substantial variability in costs between individuals but relatively little within-
person change over time for the majority.  Costs to the health system and out-of-pocket costs 
were higher with increasing asthma-related health problems and increasing age. Health 
system costs were less for patients living outside the capital city and for those in the middle 
income group relative to high and low income groups. 
Conclusions 
Those with poorly controlled asthma and the elderly require more carefully targeted strategies 
to improve their health and ensure appropriate use of resources. Access to appropriate 
services for those living outside of capital cities should be improved. Co-payments for the 
middle-income groups and those living in regional areas should be reduced to improve equity 




The management of chronic disease is a crucial issue as health systems face the challenge of 
improving health outcomes and controlling expenditure.  While individuals with chronic 
conditions generate high costs, little is known about the variation of costs and utilisation of 
services between patients.  Understanding whether high costs are due to uniformly high use 
of services, occasional acute episodes or exacerbations, or poor management and compliance 
is important in developing appropriate policy.  Higher drug co-payments, while reducing 
short run expenditure, are associated with poorer compliance and increased emergency 
department use and hospitalisation.1, 2 While estimates of disease costs are limited in their 
relevance to policy, understanding variations between individual patients can identify 
problems of access to care and the need to target programs.  
 
Asthma is a chronic disease where good control has been shown to reduce costs and improve 
health outcomes.3-5  However, many people with asthma do not use treatment appropriately 
or achieve optimal asthma control;6-9 which may be related to the cost of medication and 
medical visits.10, 11  While there have been substantial improvements in asthma management, 
as evidenced by declining mortality and hospitalisation rates, acute asthma remains a major 
reason for emergency presentation to a hospital.6  Although Australia’s Pharmaceutical 
Benefits Scheme provides universal access to subsidised drugs, out-of-pocket costs can 
become substantial when medications must be used continuously.  One study found that 
individuals presenting for acute asthma were likely to have reduced their use of preventive 
medication due to cost.10  Another showed that individuals who face lower co-payments for 
prescription drugs use more inhaled corticosteroids.7  The same study also showed that 
people living in remote areas use less asthma medication than people living in cities. 
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Our objective was to investigate the variation in costs to the health system and out-of-pocket 
costs for Australians with asthma.  It identifies sources of variation between and within 
individuals over time, as well as the extent to which this variation is associated with socio-
economic characteristics and health status.  A secondary objective was to investigate whether 
routine administrative data can be augmented by survey data to shed light on costs associated 




A longitudinal observational study of asthma-related health care costs and utilisation was 
conducted in New South Wales (NSW), Australia between 2002 and 2005.  A mixed 
recruitment method was used; a random community sample of 274 people with asthma was 
recruited by telephone, stratified by age, sex and residential area and a sample of 60 recent 
hospital emergency department (ED) attendees for asthma (included to ensure sufficient 
numbers with severe asthma).  Participants were followed for three years using six-monthly 
postal surveys to collect self reported health measures, use of services and costs. 
Administrative data were obtained for medical services, pharmaceutical benefits and hospital 
admissions.12  Of the 334 patients, 252 (community 211, hospital 41) completed two or more 
questionnaires and consented to the use of their individual administrative data from Medicare 
Australia and the NSW Health Department Inpatient Statistics Collection (ISC). 
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Utilisation and cost measurement 
Utilisation of health services and products and the associated cost to the health system and to 




Hospital utilisation included admitted episodes and non-admitted ED attendances.  Individual 
self-reported admissions were identified in the ISC database and costs assigned based on the 
diagnoses related group (DRG) code.  In-hospital medical services for private hospital 
episodes (not included in the private hospital DRG cost weight) were costed at the Medicare 
benefit paid.  The cost for non-admitted ED visits was the national average cost for all five 
non-admitted triage categories for all diagnoses.  Patient out-of-pocket costs for hospital care 
were calculated by combining survey reported hospital costs and Medicare data for in-
hospital medical services (charge minus benefit) less the private health insurance rebates 
reported in the patient surveys.  Detailed data sources and estimation methods are reported 
elsewhere.13 
 
Out-of-hospital medical services 
The asthma-related utilisation and cost of visits to general practitioners (GP) and specialists, 
and diagnostic tests were estimated from the Medicare data.  The health system cost was the 
Medicare benefit paid and the patient cost was the difference between the benefit and the 
charge.  The proportion of all GP visits that were asthma-related was estimated from an 
additional survey completed by a sub-sample (n=135) which found that, on average 33% of 
GP visits were asthma-related.  Specific diagnostic tests which were expected to be asthma-
related were included. 
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Pharmaceuticals and equipment 
The utilisation and cost of asthma drugs were identified from survey data and individual data 
from Medicare Australia.  The Pharmaceutical Benefits Scheme benefit was used to calculate 
the cost to the health system for prescription medicines, while the patient out-of-pocket cost 
was calculated as the prescription price less the benefit.  Survey data were used to calculate 
patient out-of-pocket costs for prescription medicines mainly purchased outside the benefits 
scheme, for all non-prescription medicines and for equipment used for asthma. 
 
Asthma-related health measures 
Asthma-related health measures, collected in the six-monthly surveys, were activity 
limitations due to asthma in the past 6 months (scored from 0=no limitation to 4=extremely 
limited), sleep disturbance due to asthma in the past 4 weeks (average nights/week), short-
acting beta agonist use in the past 4 weeks (average times/day) and urgent medical visits for 
an asthma attack in the past 4 weeks.  These measures have been described previously.14  
Health related quality of life is not included in this analysis as it was only available for the 
adults, excluding 30% of the sample.  
 
Statistical analysis 
Data from the hospital and community samples were combined for all analyses.  The costs to 
the health system and patient out-of-pocket costs were analysed separately.  Factors 
associated with each cost type were investigated using generalised linear mixed models.15 
Two-part models 16, 17 were used because the distribution of each cost variable was highly 
skewed with substantial numbers of zero observations (10-20%) and a long right tail (Table 
1).  The first part modelled the probability of a positive cost using a binomial distribution 
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function with a logit link, while the second part modelled the expected cost conditional on a 
positive cost using a gamma distribution function with a log link (Appendix).  To account for 
within person correlation due to the repeated measures, the models included a random 
person-specific intercept for each part of the two-part model and the covariance of the two 
random parameters.  Estimation was by residual pseudo-likelihood using SAS Proc Glimmix 
18 and fixed effects tested with the t-test. 
 
The models aimed to identify the socio-demographic characteristics and self-reported asthma-
related health measures associated with asthma-related costs to the health system and to 
patients.  Costs from survey periods 2 to 6 were modelled as a function of hospital 
admissions at period 1 (as an indicator of asthma-related health at baseline), time varying 
health measures (asthma-related activity limitations and sleep disturbance in periods 2 to 6) 
and the baseline socio-demographic variables, sex, age-group, residential area (capital 
city/region), private health insurance and gross household income.  Hospital admission in 
period 1 was included as a lagged covariate because it was expected to be correlated with 
costs and health measures within each time period, while sleep disturbance and activity 
limitation were included as time varying covariates as both have been shown to explain 
different components of variation in asthma-specific quality of life; activity limitation 
explained substantial between-person variation and sleep disturbance explained substantial 
within-person change over time.14 The variables used for sample stratification (age, sex and 
residential area) were included in all models. The same covariates were included in both 
models (costs to the health system and patient out-of-pocket costs) and in both parts of each 
model (logistic or gamma). 
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The predicted mean cost for the whole sample was calculated as the conditional expected cost 
from the gamma part of the model times the probability of a positive cost from the logistic 
part (Appendix).  This was calculated using simulation taking 1000 random draws from the 
estimated distributions of the logistic and gamma random intercepts, with the expected cost 
estimated for each draw.  The reported expected cost is the mean of the 1000 replications. 
 
To identify if the same individuals consistently had high or low costs (within-person 
variation), we calculated the maximum within-person difference for each individual as the 






The hospital sample included more women and young adults than the community sample and 
had more asthma-related health problems (Table 2).  Compared to the Australian asthma 
population, a higher proportion of both samples used asthma medication (Table 2).  The 
survey response rate declined over time: 168 (67%) responded to all six surveys (hospital 
sample 59%; and community sample 68%).  The 11-17 years age group had the lowest rate of 
complete data (44%) and the 60-75 years age group had the highest (76%; p=0.01).  The 
costs to the health system at time-point 1 were higher for those with complete follow-up 
(median=$78) compared to those with incomplete follow-up (median=$56; p=0.07).  Patient 
out-of-pocket cost did not differ by follow-up completion.  
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Costs to the health system for asthma 
The average cost to the health system was $457 in the first six months (Table 1) with the 
majority of individuals showing relatively small within-person changes over time; for 75% of 
the sample, the maximum within-person difference was $361 or less (Table 3). 
 
The model coefficients are reported in Table 4; statistically significant effects in part 1 of the 
model indicate an association with the probability of a positive cost while statistically 
significant effects in part 2 indicate an association with the size of the cost conditional on a 
positive cost.  Two effects (activity limitations and age) were significant in both the binomial 
and gamma parts of the model, household income was significant in the binomial part only 
and three effects (admission at time-point 1, residential area and private health insurance) 
were significant in the gamma part only.  The direction of the effect is relative to the 
reference group; for example the negative coefficients for age indicate lower costs for all 
groups relative to the reference group (60-75 years) while the positive coefficient for activity 
limitation indicates that as activity limitation increases, costs also increase. 
 
Age and two asthma-related health measures (activity limitation and admission at time-point 
1) had the greatest impact on expected costs.  Figure 1 illustrates the expected costs for 
selected sub-groups.  The average six-monthly health system cost was highest for the oldest 
age-group, substantially less for the next age-group and lowest for the three youngest age 
groups.  Health system costs for the middle income group were lower relative to both the 
high and low income groups and lower for those with private health insurance relative to 
those without.  An asthma-related admission at time-point 1 had a much greater impact on 
expected health system costs than the socio-demographic variables. 
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Patient out-of-pocket costs for asthma 
The average out-of-pocket cost to patients was $78 in the first six months (Table 1) and the 
majority of individuals showed relatively small changes over time; for 75% of the sample, the 
maximum within-person difference was $132 or less (Table 3). 
 
Three effects (activity limitations, age and income) were significant in both the binomial and 
gamma parts of the patient costs model, two effects (residential area and private health 
insurance) were significant in the binomial part only and another two effects (admission at 
time-point 1 and sleep disturbance) were significant in the gamma part only (Table 4).  Only 
the effects for the two youngest age-groups were significant, indicating that children had 
lower patient costs relative to the reference group (60-75 years) but that the adult groups did 
not differ significantly. 
 
Two asthma-related health indicators (activity limitation and admission at time-point 1) had 
the greatest impact on expected costs to patients.  The average six-monthly patient out-of-
pocket cost showed a gradient with household income where the high income group had the 
highest costs and the low income group had the lowest (Figure 1).  Patient costs for those 
with private health insurance were slightly higher relative to those without.  An asthma-
related admission at time-point 1 had a much greater impact on expected patient out-of-




By modelling routine administrative data augmented with survey data, we found that health 
care costs for asthma varied between individuals. Increasing activity limitations, age and 
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household income were associated with a higher probability of incurring costs, both health 
system and out-of-pocket. Activity limitations, age, and previous admission were associated 
with higher health system and out-of-pocket costs.  The higher cost for those with evidence of 
poor asthma control is not surprising, and the higher cost for older people is consistent with 
other Australian research.6  Costs to the health system were less for those living outside the 
capital city and for those with private health insurance, while the probability of an out-of-
pocket cost was higher.  The higher health system costs for capital city residents may relate to 
supply or demand factors.  Those living outside the city may be unable to access the same 
level of services or there may be differences in asthma-related problems not captured by our 
measures.  It is unlikely that holding private health insurance leads to lower service use for 
this condition in the Australian system, and this finding probably reflects the better health of 
the insured. Further research directly investigating access would enhance interpretation for 
informing policy. 
 
Average patient out-of-pocket costs were not large.  A minority had high expenditure, 
predominantly for medication.  These costs will impose a greater burden on low and middle 
income groups.  However, income related variation also was evident in health system costs, 
after adjusting for age and health status.  This may be due to our health status measures not 
being sufficiently sensitive to real differences or it could indicate the impact of co-payments 
on the mid-income group, consistent with other Australian research.7, 10, 19   
 
These results should be interpreted with caution as the causal direction of associations can be 
difficult to determine in an observational study.  The health status measures were limited as 
data collection did not include clinical measures and the models excluded measures directly 
affecting costs, such as urgent medical visits and the use of short-acting beta agonists.  The 
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recruitment strategy intentionally over-sampled people with severe asthma in order to have 
sufficient numbers of such patients.  Thus our results cannot be extrapolated to all asthma 
patients in Australia. 
 
There were substantial variations in the costs and utilisation and many high users remain high 
users over time, thus generating high costs.  To the extent that the high use group have more 
severe asthma and/or poorer control there is a need for better targeted asthma management 
strategies such as policies to improve compliance and a greater understanding of patient 
preferences about asthma medication.20, 21 However, the differences in use of health care was 
only partially explained by the asthma severity and control measures. Residents outside the 
capital city are lower service users, suggesting poorer access to services. Further, although 
there is pro-poor bias in service use (the low income group did not incur significantly lower 
service use than the high income group), the middle income group used fewer services.  Out-
of-pocket costs may be a deterrent as this group are expected to meet higher co-payments.  
 
There are three issues warranting policy attention. Those with poorly controlled asthma and 
the elderly require more carefully targeted strategies to improve their health and ensure the 
appropriate use of resources.  Access to appropriate services for those living outside of 
capital cities should be improved. Co-payments for the middle-income groups and those 
living in regional areas should be reduced to improve equity in the use of services.
 13 
References 
1 Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug 
benefits.[see comment]. N Engl J Med 2006;354:2349-59 
 
2 Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription 
drug cost-sharing among poor and elderly persons.[see comment]. JAMA 
2001;285:421-9 
 
3 Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42 
 
4 Lane S, Molina J, Plusa T. An international observational prospective study to 
determine the cost of asthma exacerbations (COAX). Respir Med 2006;100:434-50 
 
5 Williams AE, Lloyd, A. C., Watson, L., Rabe, K. F. Cost of scheduled and 
unscheduled asthma management in seven European Union countries. Eur Respir Rev 
2006;15: 4-9 
 
6 Australian Centre for Asthma Monitoring. Asthma in Australia 2005. Canberra: 
Australian Institute for Health and Welfare,2005 
 
7 Australian Centre for Asthma Monitoring. Patterns of asthma medication use in 
Australia. Canberra: Australian Institute of Health and welfare,2007 
 
8 Partridge MR, van der Molen T, Myrseth S-E, Busse WW. Attitudes and actions of 
asthma patients on regular maintenance therapy: The INSPIRE study. BMC 
Pulmonary Medicine 2006;6:13 
 
9 Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 
1999: The asthma insights and reality in Europe (AIRE) study.[see comment]. Eur 
Respir J 2000;16:802-7 
 
10 Goeman DP, Aroni RA, Stewart K, et al. Patients' views of the burden of asthma: A 
qualitative study. Med J Aust 2002;177:295-9 
 
11 Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding 
the patient's perspective? BMC Pulmonary Medicine 2007;7:8 
 
12 Kenny P, Lancsar E, Hall J, King M, Chaplin M. The individual and health sector 
costs of asthma: The first year of a longitudinal study in New South Wales. Aust N Z J 
Public Health 2005;29:429-35 
 
13 Kenny P, Hall J, King M. Variation in the costs of healthcare for chronic disease in 
Australia: The case of asthma. Working Paper 2008/7. Sydney: Centre for Health 
Economics Research and Evaluation, 2008 
 
14 King M, Kenny P, Marks G. Measures of asthma control and quality of life: 
Longitudinal data provide practical insights into their relative usefulness in different 
research contexts. Qual Life Res 2009;in press 
 
 14 
15 McCulloch CE, Searle SR. Generalized, linear, and mixed models. New York: John 
Wiley & Sons, 2001 
 
16 Buntin MB, Zaslavsky AM. Too much ado about two-part models and 
transformation?: Comparing methods of modeling Medicare expenditures. J Health 
Econ 2004;23:525-42 
 
17 Cooper NJ, Lambert PC, Abrams KR, Sutton AJ. Predicting costs over time using 
bayesian markov chain monte carlo methods: An application to early inflammatory 
polyarthritis. Health Econ 2007;16:37-56 
 
18 SAS Institute Inc. The glimmix procedure, june 2006. SAS Institute Inc., 2006. 
http://support.sas.com/rnd/app/papers/glimmix.pdf (last checked 16 November 2007 
2007) 
 
19 Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of 
co-payment increases on dispensings of government-subsidised medicines in 
Australia. Pharmacoepidemiology and Drug Safety 2008;in press: 
 
20 King MT, Hall J, Lancsar E, et al. Patient preferences for managing asthma: Results 
from a discrete choice experiment. Health Econ 2007;16:703-17 
 
21 Lancsar EJ, Hall JP, King MT, et al. Using discrete choice experiments to investigate 







The authors thank Ajsa Mahmic and Meredyth Chaplin who contributed to establishing study 
procedures and data collection, and Philip Haywood and staff at the Emergency Departments 
at Royal Prince Alfred Hospital, the Newcastle Mater Hospital and Liverpool Hospital, who 
enabled recruitment of some study participants. The study received funding from the 
Cooperative Research Centre for Asthma and a National Health and Medical Research 






  ( )ijijp θBernoulli~  







11logit αδαθ  
Part Two: 
  ( ) ( )ijijijij ba ,Gamma~0>ΥΥ  





µ ==  





















































for j=1 to 5 observations (surveys 2 to 6), i=1 to N individuals and k=1 to K covariates.  The 
α’s and β’s are the regression parameters for part 1 and part 2 respectively. δi1 is the random 
intercept term for part 1 (the random person effect for the occurrence of cost) and 21σ  is the 
associated variance. δi2 is the random intercept term for part 2 (the random person effect for 
the magnitude of cost conditional on a positive cost) and 22σ  is the associated variance. 21σσ  
is the covariance of the two random intercepts. 
 






































































This was calculated using simulation, where 1000 random draws were taken from the 
estimated distributions of the two random effects and the equation estimated for each draw. 





Table 1: Study response* and distribution of six-monthly costs† over time 
 Data collection wave 















Cost to the health system 
Mean 457 461 402 388 596 379 
Standard deviation 1,429 1,664 1,176 1,055 1,993 1,190 
Maximum 14,008 16,185 12,220 11,591 15,675 13,126 
Quartile 3 274 241 257 281 326 315 
Median 71 84 75 89 106 100 
Quartile 1 16 31 17 22 26 27 
Minimum 0 0 0 0 0 0 
% = zero 11 10 12 11 10 12 
Cost to patients 
Mean 78 84 82 77 113 117 
Standard deviation 145 148 174 139 500 406 
Maximum 1,426 1,824 2,186 1,428 6,775 5,045 
Quartile 3 83 95 97 82 100 120 
Median 39 48 40 40 41 31 
Quartile 1 14 16 12 12 13 8 
Minimum 0 0 0 0 0 0 
% = zero 12 12 12 14 11 20 
* Subjects with all data sources available at each 6-monthly survey period 
† 2002 Australian dollars 
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Table 2: Characteristics of the sample at recruitment and comparable characteristics 


























































































Private health insurance (hospital) 46 50 49 50 





















Gross weekly household income: 









Current smoker (%of 162 adults) 23 11 13 25 
Use of asthma medication (past 2 weeks) 























































Urgent medical visit for asthma (past month) 












Activity limitation due to asthma 








Sleep disturbance due to asthma 
(past month, average nights/week) 
1.5 (2.3) 0.7 (1.2) 0.8 (1.5)  
Short-acting beta agonist use 
(past month, average times/day) 
2.0 (1.8) 1.1 (1.4) 1.3 (1.5)  
* Estimated from the Australian National Health Survey 2001. 
† Australian Institute of Health and Welfare. Statistical snapshots of people with asthma in Australia 2001. 
Canberra: Australian Institute of Health and Welfare; 2007. 
§ Australian Centre for Asthma Monitoring. Asthma in Australia 2005. Canberra: Australian Institute for Health 
and Welfare; 2005. Report No.: ACM 6. 
¶ Excluding those with missing data. 
** 0=no limitation, 4=Extremely limited. 
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Table 3: Maximum within-person difference* in health system and out-of-pocket costs for 
individuals over 6 data collection waves 
 Maximum Difference in 
Health System Costs† 
n=252 
Maximum Difference in 
Patient out-of-pocket costs† 
n=252 
Mean (standard deviation) 658 (1768) 144 (434) 
Maximum 13,924 6,444 
90th percentile 1704 270 
75th percentile 361 132 
Median 155 68 
25th percentile 62 30 
10th percentile 22 10 
Minimum 0 0 
*Cost at the most expensive time-point minus the cost at the least expensive time-point. 
† 2002 Australian dollars. 
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Table 4: Asthma costs per 6 month survey period (surveys 2 to 6): model coefficients and 
standard errors from a two-part binomial logit and gamma log model (n=252). 
 Health system Patient out-of-pocket 




Part 1 Binomial model 
Intercept 6.51*** 1.14 2.04*** 0.56 
Asthma-related health measures 
Activity limitations† 0.94*** 0.26 0.50* 0.20 
Sleep disturbance† 0.08 0.17 0.10 0.12 
Admission survey 1 -0.50 0.58 0.61 0.65 
Socio-demographic covariates 
Male -0.48 0.27 0.01 0.27 
Age 
05-10 -4.08*** 1.04 -0.89* 0.39 
11-17 -4.21*** 1.05 -0.88* 0.42 
18-39 -3.37** 1.06 -0.12 0.45 
40-59 -2.98** 1.05 0.34 0.44 
60-75 Reference  Reference  
Residential area 
Regional NSW -0.33 0.26 0.65* 0.27 
Sydney metropolitan Reference  Reference  
Private health insurance -0.05 0.27 0.64* 0.28 
Income (gross household) 
Missing -1.23* 0.53 -0.50 0.53 
$1-699 pw -0.80 0.47 -0.61 0.44 
$700-1499 pw -1.42** 0.45 -0.94* 0.43 
$1500 or more pw Reference  Reference  
Part 2 Gamma model 
Intercept 5.91*** 0.28 4.19*** 0.25 
Asthma-related health measures 
Activity limitations† 0.38*** 0.05 0.29*** 0.04 
Sleep disturbance† 0.03 0.02 0.06** 0.02 
Admission survey 1 1.75*** 0.29 0.68** 0.25 
Socio-demographic covariates 
Male -0.12 0.14 -0.12 0.13 
Age 
05-10 -1.57*** 0.22 -0.43* 0.19 
11-17 -1.41*** 0.23 -0.09 0.21 
18-39 -1.39*** 0.22 -0.09 0.20 
40-59 -0.81*** 0.20 0.02 0.18 
60-75 Reference  Reference  
Residential area 
Regional NSW -0.40** 0.14 -0.14 0.13 
Sydney metropolitan Reference  Reference  
Private health insurance -0.40** 0.15 0.00 0.13 
Income (gross household) 
Missing -0.27 0.26 -0.42 0.23 
$1-699 pw -0.08 0.22 -0.61** 0.19 
$700-1499 pw -0.36 0.22 -0.22 0.19 
$1500 or more pw Reference  Reference  
Random effects 
Binomial model intercept variance 0.64 0.20 1.10 0.23 
Gamma model intercept variance 1.00 0.12 0.76 0.08 
Covariance 0.73 0.15 0.53 0.13 
Residual 0.45 0.02 0.34 0.02 
*p<0.05; **p<0.01; ***p<0.001. 































Weekly household Income Hospital admission
time-point 1
Private Health Insurance
Figure 1: Expected costs* for asthma as predicted by models for selected sub-groups†
*2002 Australian dollar.
†All estimates for female Sydney residents reporting no activity limitation or sleep disturbance.
 
